Anti-KLF6, Splice Variant 1 [9A2] Antibody

This mouse IgG2a monoclonal antibody was generated against recombinant human KLF6 splice variant 1 (SV1), and is specific for human KLF6 SV1.

Krueppel-like factor 6 (KLF6), also known as GBF, ZF9, BCD1, CPBP, PAC1, ST12, and COPEB, is a protein that in humans is encoded by the KLF6 gene. It is a tumor suppressor gene and encodes a nuclear protein that has three zinc fingers at the end of its C-terminal domain, a serine/threonine-rich central region, and an acidic domain lying within the N-terminal region. The zinc fingers of this protein are responsible for the specific DNA binding with the guanine-rich core promoter elements. The central region is involved in activation or posttranslational regulatory pathways, and the acidic N-terminal domain is proposed to play an important role in the process of transcriptional activation.

KLF6 is capable of activating transcription approximately 4-fold either on homologous or heterologous promoters. Although wild-type KLF6 acts as a tumor suppressor, KLF6 splice variant 1 (sv1) has the opposite effect on cell proliferation, colony formation and invasion. Inhibition of KLF6 sv1 with short interfering RNA reduces tumor cell growth by 50% and decreases the number of growth and angiogenesis-related genes.

From the laboratory of Goutham Narla, MD, PhD, Icahn School of Medicine at Mount Sinai.

The Investigator's Annexe Part of The Investigator's Annexe program.

Catalog Number Product Size AVAILABILITY Price Qty
EMS002
Anti-KLF6, Splice Variant 1 [9A2] Antibody
100ug 2-3 weeks
Regular Price:$283.00
Specifications

Product Type: Antibody
Name: Anti KLF6 monoclonal antibody (9A2)
Host: Mouse
Isotype: IgG2a
Clonality: Monoclonal
Clone Name: 9A2
Specificity: This antibody recognizes Human KLF6 splice variant 1 (sv1)
Immunogen: Human KLF6 splice variant 1 recombinant protein
Format: Liquid
Purity: Protein G purified
Tested Applications: IHC, WB, ELISA
Concentration: 1 mg/mL
Amount: 100uL
Storage: Store at 4C
Shipped: Cold packs

Provider
From the laboratory of Goutham Narla, MD, PhD, Icahn School of Medicine at Mount Sinai.
Comments

Increased KLF6-SV1 expression in metastatic PCa. Western blot analysis using a KLF6-SV1–specific monoclonal antibody. Transfected KLF6-SV1 and transfected wild-type KLF6 controls were run on the same gel but were noncontiguous. Tubulin was used as the loading control for all lanes.

Adapted from: Narla, G., et al., KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis. J. Clin. Invest. 118:2711–2721 (2008).

 

References
  1. Tchirkov et al. Increased expression of the oncogenic KLF6-SV1 transcript in human glioblastoma. Clin Chem lab Med, 48, 1167, 2010.
  2. Sangodkar et al. Targeted reduction of KLF6-SV1 restores chemotherapy sensitivity in resistant lung adenocarcinoma. Lung Cancer, 66, 292, 2009.
  3. Narla, G., et al., KLF6-SV1 overexpression accelerateshuman and mouse prostate cancerprogression and metastasis. J. Clin. Invest. 118:2711–2721 (2008).
  4. DiFeo et al. A functional role for KLF6-SV1 in lung adenocarcinoma prognosis and chemotherapy response.Cancer Res, 68, 965, 2008.

If you publish research with this product, please let us know so we can cite your paper.

Loading...